Product Description
| Download Documents | |
| Product Sheet | |
| SDS |
COA Lot |
Deruxtecan is an Exatecan (Exa) derivative conjugated through a cleavable peptide linker. It is a highly potent topoisomerase I inhibitor with strong anticancer activity. Deruxtecan serves as the cytotoxic payload in antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd, Enhertu®, Daiichi Sankyo), which targets HER2 and is approved for the treatment of HER2-expressing breast (BC) and gastric cancers (GC).
This mouse serum albumin (MSA)-Deruxtecan conjugate is designed using the same linker chemistry as the protein-drug conjugates (PDCs) prepared with CellMosaic’s Protein Deruxtecan Conjugation Kit (Cat. No. CM11432). The conjugate is synthesized at CellMosaic under endotoxin-free conditions and contains an average drug-to-protein ratio of approximately 3–5 Deruxtecan molecules per MSA molecule, making it suitable for immunization and immunoassay development applications.
The final conjugate is lyophilized from PBS containing a sugar-based stabilizer to facilitate convenient shipping and long-term storage.
The product is sold as either 1 vial of 1 mg (Cat# CM52150-1MG) or 5 vials of 1 mg (Cat# CM52150-5MG). For bulk orders, please contact us for a quote.
Applications
- Assay development for detection of Deruxtecan or Deruxtecan metabolites in vitro or in vivo.
- Antibody discovery via immunization and hapten recognition.
- Indirect and competitive ELISA assay.
Key Features
- Lyophilized powder and ready for usage after reconstitution with water, no need for external buffer.
- Optimized loading with an average of 3 to 5 Deruxtecan molecules per MSA.
- Amount accurately determined by UV/HPLC analysis.
Selected References for Deruxtecan ADC and Albumin based Drug Delivery
1. Takashi Nakada, et al. Novel antibody-drug conjugates containing exatecan derivative-based cytotoxic payloads. Bioorg. Med. Chem. Lett. 2016; 26:1542–1545.
Highlight: Developed Exatecan derivative-based payloads for ADCs with potent antitumor activity and stable linker technology.
2. Yusuke Ogitani, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039–1046.
Highlight: Demonstrated the bystander killing effect of DS-8201a in HER2-heterogeneous tumors.
3. Naoki Takegawa, et al. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int. J. Cancer. 2017; 141:1682–1689.
Highlight: Showed that DS-8201a overcomes T-DM1 resistance in HER2-positive gastric cancer models.
4. Ella N. Hoogenboezem, et al. Harnessing Albumin as a Carrier for Cancer Therapies. Adv. Drug Deliv. Rev. 2018; 130:144–175.
Highlight: Reviewed albumin-based drug delivery and albumin-drug conjugate strategies for cancer therapeutics.
Frequently Asked Questions:
If you can’t find the answer you’re looking for or need information on general topics, please visit the main Frequently Asked Questions (FAQs) section.
